5. Conclusions
PDAC
Nimotuzumab combined with gemcitabine as first-line treatment option represents a safe and useful alternative for the treatment of PDAC under real-world conditions. The administration of nimotuzumab as part of possible multimodal combination of agents that target a subset of cancer-associated fibroblasts or their secreted products (e.g., TGF-